Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that urologist prescription practices for three common conditions led to nearly $410 million in excess Medicare Part D spending on higher cost and non-generic drugs in 2014.

This study discusses the rising interest in drug repositioning, particularly in response to COVID-19, and highlights various computational and experimental approaches used for repurposing existing drugs across different diseases, including rare conditions and chronic kidney disease.

This review discusses the integration of drug repurposing with personalized medicine through off-label prescribing and reports no new results, highlighting the potential for systematic exploration using omics technologies.

In this cross-sectional study at a hospital in Nandyala, researchers identified nine drugs with potential new uses, noting that Aspirin and Dapagliflozin were most frequently repurposed, and observed changes in indications, dosage, and frequency, suggesting further clinical validation is needed for safety and efficacy.

This review outlines the evolution of drug repurposing from accidental discoveries to a systematic approach enhanced by genomics and data analytics, emphasizing its accelerated relevance during the COVID-19 pandemic and exploring its global and Indian milestones, computational strategies, and future regulatory perspectives.

This review outlines the evolution and strategies of drug repurposing, highlighting its transformation from accidental discoveries to a predictive, data-driven discipline through the integration of bioinformatics and artificial intelligence, with notable applications during the COVID-19 pandemic.

Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.

This article discusses the growing public health concerns associated with the surge in online sales of prescription-only medicines, highlighting the need for regulatory action and public education to address potential risks.

This study found that switching from brand name to generic drugs raises issues like patient and specialist information gaps, lack of collaboration between physicians and pharmacists, ineffective communication, and profit motives.

Organizations help patients access discounts for expensive dermatology medications.

Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.

This review highlights brimonidine’s potential as a dermatological agent, noting its ability to improve rosacea-related facial redness and its effectiveness in various other skin conditions due to its vasoconstrictive and anti-inflammatory actions, with minimal systemic absorption and a favorable safety profile for long-term use.

Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.

In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

This article compiles internet forum posts discussing differences between brand-name and generic finasteride pills, but it presents no new clinical findings.

In this study, researchers evaluated drug-target interaction data from three major resources and developed a framework for drug repurposing, revealing associations between drug properties and therapeutic groups to aid in compound prioritization and predicting repositioning opportunities for existing drugs, particularly in cancer treatment.

This review article discusses current trends and future perspectives in drug repurposing, highlighting its potential to discover novel treatments for unmet medical needs by identifying new uses for existing drugs, which benefits from faster development timelines and established safety profiles.

This study found that big chain pharmacies in Pennsylvania charged significantly higher prices for generic BPH medications compared to independent pharmacies, which had more regional price variation.

In this study, the researchers performed a comparative analysis of drug-target interaction data from multiple databases to refine drug repurposing strategies, revealing potential associations between drug characteristics and therapeutic groups, and predicting repositioning opportunities for FDA-approved drugs across major cancer types.

In this article, the authors describe how drug repurposing, supported by large-scale data and artificial intelligence, can make drug discovery more cost-effective and expedient compared to traditional methods, despite certain regulatory challenges.

This review identified two promising therapeutic targets for drug repurposing to treat refractory angina in patients with angina pectoris without obstructive coronary artery disease: endothelin-1 receptor blockers and soluble guanylate cyclase stimulators.

This review article explores the use of drug repurposing as a strategy in drug discovery, highlighting its advantages such as quicker development, cost reduction, known safety profiles, and potential for addressing unmet medical needs.

This compilation reviews side effects, drug interactions, and clinical details of dermatological and related medications but does not report new research findings.

This article provides contact details and affiliations for Amy M. Karch and Fred E. Karch; it presents no new research findings.

This study reviewed 16 notable drug repurposing patent applications from 2025, highlighting potential new uses such as guanfacine for autonomic dysfunction and disulfiram for subarachnoid hemorrhage survival, though many disclosures lack peer-reviewed studies and no patents are granted.